BlackRock
PMVP icon

BlackRock’s PMV Pharmaceuticals PMVP Stock Holding History

BlackRock’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.23M Buy
919,818
+45,444
+5% +$58.3K ﹤0.01% 4293
2026
Q1 		$1.08M Sell
874,374
-220,509
-20% -$280K ﹤0.01% 4319
2025
Q4 		$1.37M Sell
1,094,883
-9,257
-0.8% -$12.4K ﹤0.01% 4222
2025
Q3 		$1.55M Sell
1,104,140
-36,452
-3% -$50.4K ﹤0.01% 4173
2025
Q2 		$1.21M Sell
1,140,592
-3,804
-0.3% -$3.73K ﹤0.01% 4195
2025
Q1 		$1.25M Sell
1,144,396
-2,088
-0.2% -$2.83K ﹤0.01% 4130
2024
Q4 		$1.73M Buy
1,146,484
+1,687
+0.1% +$2.67K ﹤0.01% 4071
2024
Q3 		$1.71M Sell
1,144,797
-17,396
-1% -$26.9K ﹤0.01% 4044
2024
Q2 		$1.88M Sell
1,162,193
-1,948,116
-63% -$3.51M ﹤0.01% 3983
2024
Q1 		$5.29M Sell
3,110,309
-119,488
-4% -$223K ﹤0.01% 3651
2023
Q4 		$10M Sell
3,229,797
-1,366,581
-30% -$3.62M ﹤0.01% 3396
2023
Q3 		$28.2M Sell
4,596,378
-80,650
-2% -$555K ﹤0.01% 2742
2023
Q2 		$29.3M Buy
4,677,028
+646,859
+16% +$3.39M ﹤0.01% 2792
2023
Q1 		$19.2M Buy
4,030,169
+578,802
+17% +$4.07M ﹤0.01% 2996
2022
Q4 		$30M Buy
3,451,367
+91,044
+3% +$970K ﹤0.01% 2803
2022
Q3 		$40M Buy
3,360,323
+2,179
+0.1% +$31.5K ﹤0.01% 2616
2022
Q2 		$47.9M Buy
3,358,144
+717,794
+27% +$10.4M ﹤0.01% 2532
2022
Q1 		$55M Buy
2,640,350
+100,526
+4% +$1.77M ﹤0.01% 2531
2021
Q4 		$58.7M Buy
2,539,824
+351,901
+16% +$8.5M ﹤0.01% 2545
2021
Q3 		$65.2M Buy
2,187,923
+269,789
+14% +$8.61M ﹤0.01% 2492
2021
Q2 		$65.5M Buy
1,918,134
+492,261
+35% +$16.4M ﹤0.01% 2520
2021
Q1 		$46.9M Buy
1,425,873
+80,858
+6% +$3.19M ﹤0.01% 2657
2020
Q4 		$82.7M Buy
1,345,015
+802,977
+148% +$31.5M ﹤0.01% 2192
2020
Q3 		$19.2M Buy
+542,038
New +$19.9M ﹤0.01% 2875

Other funds holding PMVP

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

BlackRock's PMVP Position: Q2 2026 in Review

BlackRock increased its PMV Pharmaceuticals (PMVP) stake by 5.2% in Q2 2026, buying an estimated $58.3K and bringing the position to 919,818 shares worth $1.23M. The position accounts for ﹤0.01% of the portfolio, ranked #4293.

BlackRock first reported a position in PMVP in Q3 2020 and has held it in 24 quarters since. The position peaked at $82.7M in Q4 2020. 64 funds tracked by Wall St. Rank hold PMVP as of Q2 2026.

  • BlackRock held 919,818 shares of PMV Pharmaceuticals worth $1.23M as of Q2 2026.
  • BlackRock bought 45,444 PMV Pharmaceuticals shares in Q2 2026, an estimated $58.3K.
  • PMV Pharmaceuticals made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #4293 holding.
  • BlackRock first reported a position in PMV Pharmaceuticals in Q3 2020 and has held it in 24 quarters since.
  • BlackRock's PMV Pharmaceuticals position peaked at $82.7M in Q4 2020.
  • 64 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.